Likewise, in osteosarcoma, the gain-of-function NSD2 mutations within the SET domain, including E1099K and Y1179A, exhibit a catalytically hyperactive state and promote tumor growth both in vitro and in vivo [57]. This evidence concerns the gene NSD2 and osteosarcoma.